Remynd
Clinical trials sponsored by Remynd, explained in plain language.
-
Alzheimer's drug trial halted early: what we know
Disease control TerminatedThis study tested an experimental drug called REM0046127 in people with mild to moderate Alzheimer's disease. Participants took either a high dose, low dose, or placebo for 28 days. The goal was to check safety and see how the drug affected brain signals and spinal fluid markers.…
Phase: PHASE2 • Sponsor: reMYND • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
Alzheimer's drug candidate tested for safety in healthy volunteers
Knowledge-focused TerminatedThis study tested whether the experimental medicine REM0045392 is safe and how food affects its absorption. It involved 19 healthy adults, including older participants. The study was stopped early, and no treatment benefits were measured.
Phase: PHASE1 • Sponsor: reMYND • Aim: Knowledge-focused
Last updated May 21, 2026 04:27 UTC